NMTRQ: AI 评分 48/100 — AI 分析 (4月 2026)

9 Meters Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for rare digestive diseases and gastrointestinal conditions. The company filed for liquidation under Chapter 7 bankruptcy in July 2023.

Key Facts: AI Score: 48/100 Sector: Healthcare

公司概况

概要：

9 Meters Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on rare digestive diseases, including short bowel syndrome, and gastrointestinal conditions. Its lead product, Vurolenatide, is in Phase 3 trials. The company filed for Chapter 7 liquidation in 2023, impacting its future operations and potential for drug development within the competitive biotechnology sector.

NMTRQ是做什么的？

9 Meters Biopharma, Inc. was a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies for rare and unmet needs in digestive diseases. Founded with the mission to improve the lives of patients with gastrointestinal disorders, the company focused on developing treatments for conditions like short bowel syndrome (SBS) and other debilitating digestive ailments. Its lead product candidate, Vurolenatide, a long-acting injectable glucagon-like-peptide-1 (GLP-1), reached Phase 3 clinical trials for the treatment of SBS, representing a significant milestone in its development pipeline. In addition to Vurolenatide, 9 Meters Biopharma was also developing NM-136, a humanized monoclonal antibody for obesity and related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. The company also had a partnered product, Larazotide, an 8-amino acid peptide in Phase 2 trials for multi-system inflammatory syndrome. 9 Meters Biopharma operated through licensing agreements with companies like Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. Headquartered in Raleigh, North Carolina, the company's operations came to a halt when it filed a voluntary petition for liquidation under Chapter 7 bankruptcy on July 17, 2023.

NMTRQ的投资论点是什么？

The investment thesis for 9 Meters Biopharma, Inc. is significantly impacted by its Chapter 7 liquidation filing in July 2023. With a market capitalization of $0.00B and a negative ROE of -375.6%, the company's financial viability is uncertain. The high beta of 10.00 indicates extreme volatility. While Vurolenatide was in Phase 3 trials, the bankruptcy proceedings cast doubt on its future development and potential revenue generation. Investors should be aware of the high risks associated with companies undergoing liquidation, including the potential loss of investment.

NMTRQ在哪个行业运营？

9 Meters Biopharma operated within the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and significant risks of clinical trial failures. Companies in this sector often focus on niche markets and rare diseases to gain regulatory advantages and market exclusivity. However, the company's bankruptcy filing reflects the challenges faced by smaller biotech firms in securing funding and navigating the complexities of drug development. Competitors like ADYX and BIMI operate in similar therapeutic areas, highlighting the competitive pressure in the market.

Biotechnology

Healthcare

NMTRQ有哪些增长机遇？

Advancement of Vurolenatide: Vurolenatide, a long-acting injectable glucagon-like-peptide-1 (GLP-1), was in Phase 3 clinical trials for treating short bowel syndrome (SBS). Successful completion of these trials and subsequent regulatory approval could have addressed a significant unmet need in the SBS market, estimated to reach $2.3 billion by 2028. However, the company's bankruptcy filing jeopardizes this potential growth driver.
Development of NM-136: NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders, represented a potential expansion into a large and growing market. The global obesity market is projected to reach $40 billion by 2030, driven by increasing prevalence of obesity and related comorbidities. However, the bankruptcy filing casts doubt on the continued development of this asset.
Expansion of NM-102: NM-102, a small molecule peptide designed to prevent antigens from trafficking into systemic circulation, could have addressed various autoimmune and inflammatory conditions. The market for autoimmune disease treatments is substantial, estimated at $60 billion globally. Further development of NM-102 could have opened new avenues for growth, but the bankruptcy filing impacts its future.
Partnered Product Larazotide: Larazotide, an 8-amino acid peptide in Phase 2 clinical trials for multi-system inflammatory syndrome, represented a partnered opportunity. Positive trial results and subsequent commercialization could have generated revenue through royalties or milestone payments. However, the bankruptcy filing introduces uncertainty regarding the future of this partnership and the development of Larazotide.
Licensing Agreements: 9 Meters Biopharma had licensing agreements with companies like Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. These agreements could have provided access to novel technologies and therapeutic candidates, potentially fueling future growth. However, the bankruptcy filing may impact the validity and continuation of these agreements.

Market Cap of $0.00B indicates the company's distressed financial state.
ROE of -375.6% reflects significant losses and financial instability.
Free Cash Flow of $-0.00B highlights the company's inability to generate positive cash flow.
Beta of 10.00 indicates extremely high volatility compared to the market average.
Chapter 7 bankruptcy filing on July 17, 2023, signals the company's intent to liquidate its assets.

NMTRQ提供哪些产品和服务？

Develops treatments for rare digestive diseases.
Focuses on gastrointestinal conditions with unmet needs.
Develops therapies for debilitating disorders.
Lead product candidate was Vurolenatide for short bowel syndrome.
Developing NM-136 for obesity and obesity-related disorders.
Developing NM-102 to prevent antigens from trafficking into systemic circulation.
Developing NM-003 for prevention of acute graft versus host disease.
Partnered product Larazotide for multi-system inflammatory syndrome.

NMTRQ如何赚钱？

Develops pharmaceutical products through internal research and development.
Out-licenses or partners with other companies for development and commercialization.
Generates revenue through potential future sales of approved drugs.
Relies on licensing agreements for technology and product development.

Patients with rare digestive diseases.
Healthcare providers treating gastrointestinal conditions.
Hospitals and clinics specializing in digestive disorders.
Pharmaceutical companies through licensing and partnership agreements.

Proprietary drug candidates targeting specific unmet needs.
Intellectual property protection through patents and exclusivity.
Clinical trial data supporting efficacy and safety.
Licensing agreements providing access to novel technologies.

什么因素可能推动NMTRQ股价上涨？

Ongoing: Potential for asset sales during liquidation proceedings.
Ongoing: Legal proceedings related to bankruptcy.
Ongoing: Potential for restructuring or acquisition of assets.

NMTRQ的主要风险是什么？

Ongoing: Chapter 7 bankruptcy leading to complete loss of investment.
Potential: Delisting from the OTC market.
Potential: Legal claims from creditors.
Potential: Loss of intellectual property rights.
Potential: Negative impact on reputation and future business prospects.

NMTRQ的核心优势是什么？

Proprietary drug candidates in clinical development.
Focus on rare and unmet medical needs.
Licensing agreements with other companies.
Experienced management team in drug development.

NMTRQ的劣势是什么？

Chapter 7 bankruptcy filing.
Limited financial resources.
High dependence on clinical trial outcomes.
Negative ROE and Free Cash Flow.

NMTRQ有哪些机遇？

Potential for successful clinical trial results.
Partnerships for further drug development.
Market growth in rare digestive diseases.
Advancements in biotechnology and drug delivery.

NMTRQ面临哪些威胁？

Regulatory hurdles and approval delays.
Competition from other pharmaceutical companies.
Clinical trial failures.
Economic downturn impacting healthcare spending.

NMTRQ的竞争对手是谁？

Adynxx, Inc. — Focuses on novel pain therapeutics. — (ADYX)
BIMI International Medical Inc. — Operates in the healthcare products and services sector. — (BIMI)
ContraFect Corporation — Develops therapeutic biologics for life-threatening infections. — (CFRXQ)
eFFECTOR Therapeutics, Inc. — Focuses on oncology therapeutics. — (EFTR)
IMV Inc. — Develops immunotherapies and vaccines. — (IMVIF)

Key Metrics

MoonshotScore: 48/100

Company Profile

CEO: Peter H. R. Green
Headquarters: Raleigh, US
Employees: 10
Founded: 2016

AI Insight

AI analysis pending for NMTRQ

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does 9 Meters Biopharma, Inc. do?

9 Meters Biopharma, Inc. was a clinical-stage biopharmaceutical company focused on developing treatments for rare digestive diseases and gastrointestinal conditions with unmet needs. Its lead product candidate was Vurolenatide, a long-acting injectable glucagon-like-peptide-1 (GLP-1) in Phase 3 clinical trials for short bowel syndrome (SBS). The company also developed other drug candidates for obesity, inflammatory conditions, and graft versus host disease. However, the company filed for Chapter 7 bankruptcy in July 2023, impacting its operations and future prospects.

What do analysts say about NMTRQ stock?

Given 9 Meters Biopharma, Inc.'s Chapter 7 bankruptcy filing, formal analyst coverage is likely limited or non-existent. The company's financial instability and liquidation proceedings make it a highly speculative investment. Key valuation metrics are likely negative or irrelevant. Investors should exercise extreme caution and conduct thorough due diligence before considering any investment in NMTRQ. The bankruptcy filing significantly alters the investment landscape for the company.

What are the main risks for NMTRQ?

The primary risk for 9 Meters Biopharma, Inc. is the ongoing Chapter 7 bankruptcy proceedings, which could result in a complete loss of investment for shareholders. Additional risks include delisting from the OTC market, potential legal claims from creditors, loss of intellectual property rights, and negative impact on the company's reputation. The company's financial instability and lack of revenue generation further exacerbate these risks. Investors should carefully consider these factors before investing.